09606 映恩生物－Ｂ
DUALITYBIO-B
DUALITYBIO-B
| Listing Date | 2025/04/15 |
| Listing Price | 94.600 |
Quote
Subscription Result
- Subscription Rate115.14x
- Guarantee One Lot Size10 lot
- One Lot Success Rate80.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Duality Biotherapeutics, Inc. was ncorporated in 2019, the Group is a key player in the global antibody-drug conjugate landscape, dedicated to the development of innovative therapeutics in this fast-growing drug modality to treat cancer, autoimmune diseases, and beyond. The Group have self-discovered two Core Products, namely DB-1303/BNT323, and DB-1311/BNT324, a HER2 ADC candidate targeted for HER2 cancers including endometrial cancer and breast cancer.
--
The Group have built a pipeline of 12 in-house discovered ADC candidates, comprising: seven clinical-stage ADCs with potential in a broad range of indications; two next-generation BsADCs that are expected to enter into clinical stage from 2025 to 2026; and multiple other preclinical ADCs.
--
All of the Group’s clinical-stage assets had obtained investigational new drug approvals from both the United States Food and Drug Administration and the National Medical Products Administration of the PRC and have seven ongoing global multi-regional clinical trials across 17 countries and over 230 trial sites as of March 28, 2025.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 100 |
GLOBAL OFFERING
| No. of Offer Shares | 17.33M shares |
| No. of International Offer Shares | 9.80M shares |
| No. of HK Offer Shares | 7.54M shares |
| Offer Price | $94.60 - $103.20 |
| Stock Code | 9606 |
| Sponsor(s) | Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | Morgan Stanley Asia Limited, Jefferies Hong Kong Limited, CLSA Limited, China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, ICBC International Securities Limited, BOCI Asia Limited, GF Securities (Hong Kong) Brokerage Limited, ABCI Securities Company Limited |
TIME TABLE
| Application Period | Apr 07 (Mon) - noon, Apr 10 (Thu) |
| Price Determination Date | Apr 11 (Fri) |
| Result Announcement Date | On or before Apr 14 (Mon) |
| Result Announcement Date | On or before Apr 14 (Mon) |
| Result Announcement Date | On or before Apr 15 (Tue) |
| Dealings in Shares commence on | Apr 15, 2025. (Tue) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $94.60 - $103.20 |
| Capitalization | 7.87B - 8.58B |
| NAV / share ($) | $28.79 - $30.28 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 98.9, the net proceeds raised would be HKD 1.37B, of which |
| 45% : Research, development and commercialization of Core Products, namely, DB-1303 and DB-1311 |
| 30% : Research and development of key products |
| 15% : Ｆund the continued development of our ADC technology platforms, advance other pipeline assets, and explore and develop new drug assets |
| 10% : Ｗorking capital |
IPO NEWS
| 15/04/2025 16:08 |
| {New Stock}DUALITYBIO-B(09606) ends up 116.7% at HK$205 |
| 15/04/2025 09:20 |
| {New Stock}DUALITYBIO-B(09606) opens up 91.33% at HK$181 |
| 14/04/2025 18:35 |
| {New Stock}DUALITYBIO-B(09606) ends up 82.88% on grey market |
| 14/04/2025 16:20 |
| {New Stock}DUALITYBIO-B up 60.04% at HK$151.4 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).